AMT-754

N/A

Report date: 2025/02/21 14:35:12
First In Class

Base Information

Drug NameAMT-754
Drug Alias NameAMT-754ADCE-T02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionAnti-TFDNA topoisomerase I inhibitors
TargetsTissue factorDNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMultitude Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPuzhong Discovery Medical Technology (Shanghai) Co LtdAdcendo APSMultitude Therapeutics Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A